- Market Capitalization, $K 123,471
- Shares Outstanding, K 37,991
- Annual Sales, $ 0 K
- Annual Income, $ -16,200 K
- 60-Month Beta 2.38
- Price/Sales N/A
- Price/Cash Flow N/A
- Price/Book 1.52
|Period||Period Low||Period High||Performance|
| || |
+0.66 (+25.48%)since 08/24/21
| || |
-0.28 (-7.93%)since 06/24/21
| || |
+1.48 (+83.62%)since 09/24/20
Investors need to pay close attention to ASLAN Pharmaceuticals (ASLN) stock based on the movements in the options market lately.
The rapid spread of the COVID-19 Delta variant is fostering renewed investor interest in the biotech industry. Also, with the increasing demand for treatments for other critical diseases, the industry...
Monday U.S. Featured Earnings Simulations Plus, Inc. (NASDAQ: SLP) (Q3) EPS projected for 17 cents, ...
/PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GALT, HOFV, PUBM, QFIN, and ASLN.
ASLN, CANG, ESLT, GCI, and KRYS have been added to the Zacks Rank #5 (Strong Sell) List on June 8, 2021.
ASLN, BLRX, FLXN, ICMB, and MRNS have been added to the Zacks Rank #5 (Strong Sell) List on June 4, 2021.
Bayer (BAYRY) beat estimates for earnings and revenues for the first quarter of 2021.
Kodiak Sciences (KOD) reports wider-than-expected loss for the first quarter of 2021. Pipeline development remains in focus for the company.
Catalyst's (CPRX) earnings beat estimates in the first quarter of 2021 while revenues missed the same.
Epizyme (EPZM) reports wider-than-expected loss in the first quarter of 2021 despite its revenues beating estimates.